Lu Rahman speaks to George I’ons, head of product strategy and insights at Owen Mumford Pharmaceutical Services about the findings of its recent report scoping the near-term competitive biosimilars market in the USA and Europe, and its impact on drug delivery device design.
Harmony
The available market for biosimilar manufacturers seeking to compete with original reference biologics coming off patent between late 2018 and 2023 in the USA and Europe, is considerable. However, says Owen Mumford, even where clinicians encourage the use of biosimilars for the patient, there remain some key considerations to overcome. This includes clinical confidence in the biosimilar; competitive pricing of drugs through greater competition; and patient confidence in the drug delivery device.
Owen Mumford’s study reveals the size of the near-term opportunity in competitive biosimilars markets for biologics coming off patent 2018-2023, and offers evidence that device design is a key differentiator in addressing patient adoption.